(Q39123448)

English

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study

scientific article published on 16 February 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

0 references

1 reference

based on heuristic

inferred from title

Anne-Geneviève Marcelin

13

object named as

Anne-Genevieve Marcelin

0 references

Christine Katlama

1

object named as

Christine Katlama

0 references

Dominique Costagliola

11

object named as

Dominique Costagliola

0 references

Gilles Peytavin

12

object named as

Gilles Peytavin

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

10

object named as

Anne Simon

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Marc-Antoine Valantin

3

object named as

Marc-Antoine Valantin

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

4

object named as

Cathia Soulié

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Claudine Duvivier

5

object named as

Claudine Duvivier

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Lambert Assoumou

2

object named as

Lambert Assoumou

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

8

object named as

Gilles Pialoux

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

ROCnRAL ANRS 157 Study Group

14

object named as

ROCnRAL ANRS 157 Study Group

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

Laetitia Chablais

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sami Kolta

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Patrick Mercié

9

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

language of work or name

0 references

publication date

16 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1648-1652

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Body composition changes after switching from protease inhibitors to raltegravir

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT536

21 January 2018

Identifiers

10.1093/JAC/DKT536

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39123448&oldid=1854462805"